血小板因子4(PF4)检测试剂盒(酶联免疫吸附试验法)
ELISA Kit for Platelet Factor 4 (PF4)
CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact
- 编号SEA172Mu
- 物种Mus musculus (Mouse,小鼠) 相同的名称,不同的物种。
- 实验方法双抗夹心
- 反应时长3h
- 检测范围0.156-10ng/mL
- 灵敏度最小可检测剂量小于等于0.062ng/mL.
- 样本类型Serum, platelet-poor plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下载 英文说明书 中文说明书
- 规格 48T96T 96T*5 96T*10 96T*100
- 价格 ¥ 2092 ¥ 2988 ¥ 13446 ¥ 25398 ¥ 209160
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
本试剂盒用于检测血小板因子4(PF4),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的血小板因子4(PF4)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。
样本 | 回收率范围(%) | 平均回收率(%) |
serum(n=5) | 95-105 | 101 |
EDTA plasma(n=5) | 86-93 | 90 |
heparin plasma(n=5) | 78-97 | 86 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%
线性
在定值血清及血浆样本内加入适量的血小板因子4(PF4),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中血小板因子4(PF4)含量的测定值与理论值的比率。
样本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 89-103% | 84-93% | 80-96% | 93-101% |
EDTA plasma(n=5) | 86-93% | 80-93% | 83-101% | 79-98% |
heparin plasma(n=5) | 84-98% | 93-101% | 82-101% | 93-101% |
稳定性
经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备;
2. 加样(标准品及样本)100µL,37°C孵育1小时;
3. 吸弃,加检测溶液A100µL,37°C孵育1小时;
4. 洗板3次;
5. 加检测溶液B100µL,37°C孵育30分钟;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分钟;
8. 加终止液50µL,立即450nm读数。
实验原理
将血小板因子4(PF4)抗体包被于96孔微孔板中,制成固相载体,向微孔中分别加入标准品或标本,其中的血小板因子4(PF4)与连接于固相载体上的抗体结合,然后加入生物素化的血小板因子4(PF4)抗体,将未结合的生物素化抗体洗净后,加入HRP标记的亲和素,再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的血小板因子4(PF4)呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值),计算样品浓度。
增值服务
相关产品
编号 | 适用物种:Mus musculus (Mouse,小鼠) | 应用(仅供研究使用,不用于临床诊断!) |
APA172Mu01 | 血小板因子4(PF4)活性蛋白 | Cell culture; Activity Assays. |
RPA172Mu01 | 血小板因子4(PF4)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA172Mu02 | 血小板因子4(PF4)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA172Mu01 | 血小板因子4(PF4)多克隆抗体 | WB; IHC; ICC; IP. |
PAA172Mu02 | 血小板因子4(PF4)多克隆抗体 | WB; IHC; ICC; IP. |
LAA172Mu71 | 血小板因子4(PF4)多克隆抗体(生物素标记) | WB; IHC; ICC. |
LAA172Mu81 | 血小板因子4(PF4)多克隆抗体(异硫氰酸荧光素标记) | WB; IHC; ICC; IF. |
SEA172Mu | 血小板因子4(PF4)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCA172Mu | 血小板因子4(PF4)检测试剂盒(化学发光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMA172Mu | 血小板因子4(PF4)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
KSA172Mu01 | 血小板因子4(PF4)检测试剂盒DIY材料(酶联免疫吸附试验法) | Main materials for "Do It (ELISA Kit) Yourself". |
参考文献
杂志 | 参考文献 |
Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics | Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats [PubMed: 20601223] |
Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation [PubMed: 22899170] |
PLoS One | Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation [PubMed: PMC3608633] |
Diving and Hyperbaric Medicine | Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompression [Pubmed:25311322] |
Journal of Functional Foods | A Phellinus baumii–based supplement containing Salvia miltiorrhiza Bunge improves atherothrombotic profiles through endothelial nitric oxide synthase and cyclooxygenase pathwaysin vitro and in vivo [science:S1756464616300676] |
Plos one | Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury [pubmed:27583400] |
international journal of molecular sciences | Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation. [pubmed:28272338] |
Experimental and Therapeutic Medicine | Feasibility of improving platelet‑rich plasma therapy by using chitosan with high platelet activation ability [pubmed:28450960] |
Reproductive Toxicology | Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats [Pubmed: 30528429] |
INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation [Pubmed: 30857843] |
Available at SSRN 3335365 | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers [] |
journal of biotechnology | Newly Identified HNP‐F from Human Neutrophil Peptide 1 Promotes Hemostasis [Pubmed: 30927490] |
Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation [] |
journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers [Pubmed: 32812629] |
Marine Drugs | The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents [Pubmed: 31533230] |
Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices [Pubmed: 31838449] |
Nat Commun | The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets [34099640] |
Vaccine | The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats [Pubmed:35183388] |